Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 7/20 | 0.45 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761180 | 1.00 | CDC7 (0.45) | CDC7DBF4CHEK1KMT2AHASPIN | |
| SCHEMBL5095235 | 0.95 | CDC7 (0.47) | CDC7DBF4CHEK1KMT2AHASPIN | |
| SCHEMBL5095241 | 0.95 | CDC7 (0.47) | CDC7DBF4CHEK1KMT2AHASPIN | |
| SCHEMBL5100617 | 0.94 | CHEK1 (0.42) | CDC7DBF4CHEK1KMT2AHASPIN | |
| SCHEMBL5100603 | 0.94 | CHEK1 (0.42) | CDC7DBF4CHEK1KMT2AHASPIN | |
| SCHEMBL5095489 | 0.86 | CHEK1 (0.43) | CDC7DBF4CHEK1KMT2AHASPIN | |
| SCHEMBL5095482 | 0.86 | CHEK1 (0.43) | CDC7DBF4CHEK1KMT2AHASPIN | |
| Hydrochloric Acid SCHEMBL5089709 | 0.85 | CHEK1 (0.44) | CDC7DBF4CHEK1KMT2AHASPIN | |
| Hydrochloric Acid SCHEMBL5089699 | 0.85 | CHEK1 (0.44) | CDC7DBF4CHEK1KMT2AHASPIN | |
| SCHEMBL5095393 | 0.85 | CHEK1 (0.42) | CDC7DBF4CHEK1KMT2AHASPIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960399-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Pfizer Italia S.r.l. (IT) | 2008-08-27 | — | — | EP | claimed |
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | claimed |
| WO-2007054508-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | PFIZER ITALIA SRL (IT) | 2007-05-18 | — | — | WO | claimed |
| US-7371862-B2 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2008-05-13 | — | — | US | disclosed |
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112020-A1 | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K20, MAP3K6, MAP3K1 | CDC7 128/4885DBF4 1882/4885CHEK1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.